Nifty
Sensex
:
:
24565.35
80599.91
-203.00 (-0.82%)
-585.67 (-0.72%)

Pharmaceuticals & Drugs

Rating :
56/99

BSE: 540679 | NSE: SMSLIFE

1092.50
01-Aug-2025
  • Open
  • High
  • Low
  • Previous Close
  •  1138.6
  •  1138.6
  •  1088.1
  •  1132.70
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  912
  •  1009026.7
  •  1749.65
  •  861.55

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 328.74
  • 16.35
  • 10
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 411.24
  • 0.14%
  • 1.67

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 71.41%
  • 2.77%
  • 25.54%
  • FII
  • DII
  • Others
  • 0.03%
  • 0.00%
  • 0.25%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • 3.25
  • -4.39

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • 4.21
  • -2.00

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • -2.22
  • -28.90

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • -
  • 16.83
  • 17.71

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • -
  • 1.46
  • 1.42

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • -
  • 8.78
  • 8.97

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 25
Mar 24
Var%
Dec 24
Dec 23
Var%
Sep 24
Sep 23
Var%
Jun 24
Jun 23
Var%
Net Sales
89.11
89.99
-0.98%
84.60
72.05
17.42%
78.46
69.26
13.28%
92.55
74.65
23.98%
Expenses
81.69
78.63
3.89%
71.85
62.76
14.48%
69.90
61.40
13.84%
76.26
72.12
5.74%
EBITDA
7.42
11.36
-34.68%
12.75
9.29
37.24%
8.56
7.86
8.91%
16.28
2.53
543.48%
EBIDTM
8.33%
12.62%
15.08%
12.90%
10.91%
11.35%
17.60%
3.39%
Other Income
2.34
2.36
-0.85%
0.06
0.58
-89.66%
2.04
0.34
500.00%
0.44
0.61
-27.87%
Interest
2.03
2.84
-28.52%
2.14
2.34
-8.55%
2.14
2.81
-23.84%
2.41
2.18
10.55%
Depreciation
3.80
3.78
0.53%
3.76
3.73
0.80%
3.76
3.73
0.80%
3.68
3.70
-0.54%
PBT
3.93
7.10
-44.65%
6.92
3.81
81.63%
4.70
1.66
183.13%
10.64
-2.73
-
Tax
0.45
0.63
-28.57%
2.06
-0.31
-
1.40
2.10
-33.33%
3.54
1.10
221.82%
PAT
3.48
6.48
-46.30%
4.85
4.12
17.72%
3.30
-0.44
-
7.10
-3.83
-
PATM
3.91%
7.20%
5.74%
5.72%
4.20%
-0.64%
7.67%
-5.13%
EPS
9.83
19.53
-49.67%
18.08
14.24
26.97%
15.46
2.25
587.11%
23.15
-5.94
-

Annual Results

Standalone Figures in Rs. Crores /

Consolidated
Description
TTM
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Net Sales
344.72
305.96
315.56
350.07
265.59
260.78
377.85
Net Sales Growth
12.67%
-3.04%
-9.86%
31.81%
1.84%
-30.98%
 
Cost Of Goods Sold
154.06
151.16
171.41
194.68
137.04
157.88
255.87
Gross Profit
190.66
154.80
144.16
155.39
128.55
102.90
121.98
GP Margin
55.31%
50.59%
45.68%
44.39%
48.40%
39.46%
32.28%
Total Expenditure
299.70
274.74
286.74
315.54
235.35
235.38
343.09
Power & Fuel Cost
-
30.45
29.28
30.02
21.56
20.48
25.93
% Of Sales
-
9.95%
9.28%
8.58%
8.12%
7.85%
6.86%
Employee Cost
-
49.27
43.43
39.90
30.66
26.56
23.11
% Of Sales
-
16.10%
13.76%
11.40%
11.54%
10.18%
6.12%
Manufacturing Exp.
-
28.10
28.22
35.77
29.16
20.26
24.94
% Of Sales
-
9.18%
8.94%
10.22%
10.98%
7.77%
6.60%
General & Admin Exp.
-
10.04
8.32
7.47
6.95
5.69
5.84
% Of Sales
-
3.28%
2.64%
2.13%
2.62%
2.18%
1.55%
Selling & Distn. Exp.
-
5.23
5.25
6.97
6.75
4.30
6.74
% Of Sales
-
1.71%
1.66%
1.99%
2.54%
1.65%
1.78%
Miscellaneous Exp.
-
0.48
0.84
0.72
3.23
0.21
0.66
% Of Sales
-
0.16%
0.27%
0.21%
1.22%
0.08%
0.17%
EBITDA
45.01
31.22
28.82
34.53
30.24
25.40
34.76
EBITDA Margin
13.06%
10.20%
9.13%
9.86%
11.39%
9.74%
9.20%
Other Income
4.88
3.83
3.07
1.74
1.78
2.28
2.51
Interest
8.72
10.26
6.87
6.23
4.60
5.15
5.51
Depreciation
15.00
14.94
10.79
10.01
7.86
7.86
6.38
PBT
26.19
9.85
14.24
20.04
19.57
14.67
25.39
Tax
7.45
3.52
5.22
7.43
6.01
4.48
7.54
Tax Rate
28.45%
35.74%
31.46%
22.70%
30.71%
30.54%
29.70%
PAT
18.73
9.10
11.47
25.32
13.56
10.18
17.85
PAT before Minority Interest
20.10
6.33
11.38
25.30
13.56
10.18
17.85
Minority Interest
1.37
2.77
0.09
0.02
0.00
0.00
0.00
PAT Margin
5.43%
2.97%
3.63%
7.23%
5.11%
3.90%
4.72%
PAT Growth
195.89%
-20.66%
-54.70%
86.73%
33.20%
-42.97%
 
EPS
62.43
30.33
38.23
84.40
45.20
33.93
59.50

Results Balance Sheet

Standalone Figures in Rs. Crores /

Consolidated
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Shareholder's Funds
176.81
168.61
152.23
129.22
115.73
106.33
Share Capital
3.02
3.02
3.02
3.02
3.02
3.02
Total Reserves
173.79
165.59
149.21
126.19
112.71
103.31
Non-Current Liabilities
52.32
73.11
56.38
59.00
50.06
38.60
Secured Loans
33.15
51.34
35.38
34.19
31.76
21.83
Unsecured Loans
0.00
3.60
4.95
4.95
4.95
5.38
Long Term Provisions
4.74
4.10
3.51
3.04
2.70
2.33
Current Liabilities
148.81
137.06
143.06
118.76
90.10
131.56
Trade Payables
59.13
59.67
77.89
67.03
49.03
97.91
Other Current Liabilities
37.01
42.48
28.55
25.44
15.57
13.59
Short Term Borrowings
46.76
30.11
27.14
20.20
20.96
12.77
Short Term Provisions
5.91
4.80
9.48
6.09
4.54
7.30
Total Liabilities
394.76
398.38
364.37
306.98
255.89
276.49
Net Block
223.34
228.36
142.03
129.78
124.13
117.43
Gross Block
290.23
280.62
177.21
164.01
149.59
135.78
Accumulated Depreciation
66.89
52.26
35.18
34.24
25.47
18.34
Non Current Assets
235.25
235.77
200.73
176.01
145.61
127.63
Capital Work in Progress
6.00
0.85
51.18
38.31
15.76
3.29
Non Current Investment
0.04
0.04
0.04
0.04
0.04
0.95
Long Term Loans & Adv.
5.87
6.53
7.48
6.91
5.68
4.90
Other Non Current Assets
0.00
0.00
0.00
0.97
0.00
1.05
Current Assets
159.52
162.62
163.64
130.97
110.28
148.86
Current Investments
0.00
0.00
0.00
0.00
0.00
0.00
Inventories
81.21
86.23
84.81
61.63
64.30
81.17
Sundry Debtors
51.35
46.06
33.83
34.15
21.61
41.32
Cash & Bank
1.49
4.41
4.39
11.06
7.59
2.61
Other Current Assets
25.47
2.56
2.99
11.60
16.78
23.76
Short Term Loans & Adv.
23.65
23.35
37.62
12.52
11.13
13.05
Net Current Assets
10.71
25.55
20.57
12.21
20.18
17.30
Total Assets
394.77
398.39
364.37
306.98
255.89
276.49

Cash Flow

Standalone Figures in Rs. Crores /

Consolidated
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Cash From Operating Activity
24.31
14.70
-11.24
35.17
14.55
29.99
PBT
9.85
14.24
20.04
19.57
14.67
25.38
Adjustment
21.49
15.87
14.05
10.38
11.24
9.34
Changes in Working Capital
-4.03
-12.15
-37.62
10.16
-8.30
1.94
Cash after chg. in Working capital
27.31
17.95
-3.53
40.10
17.61
36.67
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-3.00
-3.26
-7.71
-4.93
-3.06
-6.67
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-18.45
-31.29
-7.14
-26.23
-27.02
-44.01
Net Fixed Assets
-13.77
-35.04
-14.94
-13.35
-15.06
Net Investments
0.00
0.01
2.57
0.00
0.92
Others
-4.68
3.74
5.23
-12.88
-12.88
Cash from Financing Activity
-6.56
16.89
10.83
-2.55
12.45
15.37
Net Cash Inflow / Outflow
-0.71
0.29
-7.55
6.39
-0.03
1.35
Opening Cash & Equivalents
1.28
0.99
8.54
2.15
2.17
0.82
Closing Cash & Equivalent
0.57
1.28
0.99
8.54
2.15
2.17

Financial Ratios

Standalone /

Consolidated
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Book Value (Rs.)
584.84
557.71
503.53
427.40
382.80
351.70
ROA
1.60%
2.98%
7.54%
4.82%
3.83%
6.45%
ROE
3.66%
7.09%
17.98%
11.07%
9.17%
16.78%
ROCE
7.42%
9.45%
18.42%
12.96%
11.91%
20.14%
Fixed Asset Turnover
1.19
1.56
2.28
1.88
2.04
3.07
Receivable days
52.44
40.71
31.92
34.48
39.53
36.22
Inventory Days
90.14
87.15
68.75
77.87
91.38
71.14
Payable days
143.42
146.47
135.85
154.56
169.86
99.23
Cash Conversion Cycle
-0.85
-18.60
-35.18
-42.21
-38.95
8.13
Total Debt/Equity
0.55
0.59
0.51
0.50
0.55
0.44
Interest Cover
1.96
3.42
6.26
5.26
3.85
5.61

News Update:


  • SMS Lifesciences India receives EIR with VAI for Telangana facility
    16th Jul 2025, 14:42 PM

    The company has received EIR from the USFDA for its API manufacturing facility (Unit 1) located at Kazipally

    Read More
  • USFDA completes inspection at SMS Lifesciences’ API manufacturing facility in Telangana
    9th May 2025, 16:42 PM

    There is no impact on financial, operations or other activities of the company pursuant to the observation

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.